Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, Satsuma President and Chief Executive Officer, will present a corporate update at the Evercore ISI HealthCONx Investor Conference, taking place December 3-5, 2019 in Boston.
| Evercore ISI HealthCONx Conference | |||
| Date: | Tuesday, December 3, 2019 | ||
| Time: | 12:50pm Eastern Time on Track 3: Stuart Room | ||
| Location: | Four Seasons Hotel, Boston, MA | ||
| Webcast: | |||
A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at . The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The Company believes STS101 would, if approved, be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, recently completed a Phase 1 clinical trial, and is currently in Phase 3 development.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
